AMF Share Price

Open 0.05 Change Price %
High 0.05 1 Day 0.00 0.00
Low 0.05 1 Week 0.00 0.00
Close 0.05 1 Month 0.00 0.00
Volume 23840 1 Year 0.00 0.00
52 Week High 13.55
52 Week Low 10.94
AMF Important Levels
Resistance 2 0.05
Resistance 1 0.05
Pivot 0.05
Support 1 0.05
Support 2 0.05
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
SC 60.83 -0.44%
PRE 0.64 0.00%
PRE 0.64 0.00%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
ORA 1.73 13.07%
ORA 1.73 13.07%
More..
TSE Canada Top Losers Stocks
COM 3.26 -34.67%
COM 3.26 -34.67%
COM 3.26 -34.67%
COM 3.26 -34.67%
HE 0.02 -33.33%
HE 0.02 -33.33%
TPL 0.02 -33.33%
TPL 0.02 -33.33%
GBV 0.46 -24.59%
CQE 0.14 -12.50%
More..

Amorfix Life Sciences Ltd (TSE: AMF)

AMF Technical Analysis 2
As on 13th Jul 2015 AMF Share Price closed @ 0.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.16 & Buy for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMF Target for August
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
AMF Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.amorfix.com
AMF Address
AMF
3403 American Drive
Mississauga, ON L4V 1T4
Canada
Phone: 416-847-6898
Fax: 416-847-6899
AMF Latest News
ProMIS Neurosciences Inc. (TSX:PMN) MF Rank in the Spotlight   Buckeye Business Review   - 21st Aug 17
Promis Neurosciences $3.84 million Financing. Elliot Goldstein Released Aug 16 ...   Weekly Register   - 18th Aug 17
ProMIS Neurosciences Increases Size of Private Placement to $6 Million   Nasdaq   - 02nd Aug 17
ProMIS Neurosciences Announces CDN$3 Million Best-Efforts Private Placement   Canada NewsWire (press release)   - 20th Jul 17
ProMIS Neurosciences Provides Second Quarter Update for 2017 and Outlook for ...   Canada NewsWire (press release)   - 10th Jul 17
ProMIS Neurosciences Announces Q1 2017 Quarterly Results   Canada NewsWire (press release)   - 09th May 17
ProMIS Neurosciences Announces Fiscal 2016 Annual Results   Canada NewsWire (press release)   - 15th Mar 17
Rise in small-cap biotech signals return to fundamentals, says Next Edge's ...   Cantech Letter   - 05th Aug 16
Amorfix Life Sciences, soon to be renamed ProMIS Neurosciences, announces ...   Stockhouse   - 07th Jul 15
0.1851   MarketWatch   - 28th Sep 11
Interactive Technical Analysis Chart Amorfix Life Sciences Ltd ( AMF TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amorfix Life Sciences Ltd
AMF Business Profile
Amorfix Life Sciences Ltd. develops therapeutics and diagnostic devices for misfolded protein diseases. It develops antibodies and vaccines that recognize misfolded protein in amyotrophic lateral sclerosis (ALS), as well as in various CJD and cancer. The company's diagnostic programs include EP-AD CSF Diagnostic Test, an assay for the detection of the aggregated form of Aß in human cerebrospinal fluid and mild cognitive impairment; A4, an ultra-sensitive assay for detecting aggregated Aß in animal models of Alzheimer's disease (AD); blood test for use as a diagnostic tool for ALS; and liver cancer screening assay. It also offers custom assay development services. The company also has strategic alliances with Epitomics Inc. to develop immunotherapeutics to various proteins; and license agreement with Biogen Idec for developing therapeutics to treat ALS. Amorfix Life Sciences Ltd. was founded in 2004 and is based in Mississauga, Canada.